Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma - A feasibility study

Anti-Cancer Drugs

Volumn 11, Issue 4, 2000, Pages 257-261

  Knuuttila, Aija ^a   Ollikainen, Tiina ^b   Halme, Maija ^a   Mali, Pekka ^c   Kivisaari, Leena ^a   Linnainmaa, Kaija ^b   Jekunen, Antti ^c   Mattson, Karin ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Chemotherapy; Docetaxel; Irinotecan; Mesothelioma; Mesothelioma cell lines

Indexed keywords

CISPLATIN; DOCETAXEL; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG TOXICITY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; MALE; NAUSEA; NEUTROPENIA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; VOMITING;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PACLITAXEL; PLEURAL NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 0034130540     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200004000-00005     Document Type: Article

References (15)

1. 1. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996; 14: 1007-17.
2. 2. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992; 65: 956-60.
3. 3. Halme M, Knuuttila A, Vehmas T, et al. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 1999; 80: 1781-5.
4. 4. Nakano T, Shinjo M, Togawa N, et al. A pilot phase II study of irinotecan (CPT-11) in combination with cisplatin administered intravenously to patients with malignant mesothelioma (abstract). Philadelphia, PA: International Mesothelioma Interest Group (IMIG), 1997.
5. 5. Shimada Y, Rothenberg M, Hilsenbeck SG, Burris III HA, Degen D, Von Hoff DD. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anti-Cancer Drugs 1994; 5: 202-6.
6. 6. Ollikainen T, Knuuttila A, Suhonen S, et al. In vitro sensitivity of normal human mesothelial and malignant mesothelioma cells lines to four new chemotherapeutic agents. Anti-Cancer Drugs 2000; 2: 93-9.
7. 7. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996; 14: 1-12.
8. 8. Belani C, Adak S, Aisner S, Stella PJ, Levitan N, Johnson DH. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol 1999; 18 (abstr.)
9. 9. Nakano T, Chahinian AP, Shinjo M, et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999; 85: 2375-84.
10. 10. Maksymiuk AW, Marschke Jr RF, Tazelaar HD, et al. Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 1998; 21: 610-3.
11. 11. Hand A, Pelin K, Mattson K, Linnainmaa K. Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines. Anti-Cancer Drugs 1995; 6: 77-82.
12. 12. Mäenpää J, Käär K, Kivinen S, Pohto M, Jekunen A. Docetaxel and CPT-11 for recurrent ovarian cancer - a phase II study. Proc Am Soc Clin Oncol 1999; 18 (abstr).
13. 13. Society of Japanese Pharmacopoeia. Irinotecan hydrochloride, summary basis of approval. Tokyo: Pharmaceuticals Affairs Bureau 1996: 105.
14. 14. Huncharek M, Kelsey K, Mark EJ, et al. Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital. Anticancer Res 1996; 16: 1265-8.
15. 15. Knuuttila A, Halme M, Kivisaari L, Kivisaari A, Salo J, Mattson K. The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma. Lung Cancer 1998; 22: 215-25.